Amir Qaseem,Timothy J Wilt,Robert Rich,Linda L Humphrey,Jennifer Frost,Mary Ann Forciea,Clinical Guidelines Committee of the American College of Physicians and the Commission on Health of the Public and Science of the American Academy of Family Physicians,Nick Fitterman,Michael J Barry,Carrie A Horwitch,Alfonso Iorio,Robert M McLean,Cynthia Boyd,Devan Kansagara,Scott Manaker,Sandeep Vijan,Patricia Czapp,Ada Denise Stewart,David T O’Gurek,Joseph L Perez,Margot L Savoy,Kenneth W Lin,Jason M Matuszak,Ranit Mishori,Daron W Gersch,Clare A Hawkins,Beulette Y Hooks,Robyn Liu,Shannon Dowler,Shani Muhammad,Tobie-Lynn Smith,James Stevermer,Carolyn Gaughan,Vivian Jiang,Aisha Harris

Abstract:Description: The American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) jointly developed this guideline to present the evidence and provide clinical recommendations based on the benefits and harms of higher versus lower blood pressure targets for the treatment of hypertension in adults aged 60 years or older. Methods: This guideline is based on a systematic review of published randomized, controlled trials for primary outcomes and observational studies for harms only (identified through EMBASE, the Cochrane Database of Systematic Reviews, MEDLINE, and ClinicalTrials.gov), from database inception through January 2015. The MEDLINE search was updated through September 2016. Evaluated outcomes included all-cause mortality, morbidity and mortality related to stroke, major cardiac events (fatal and nonfatal myocardial infarction and sudden cardiac death), and harms. This guideline grades the evidence and recommendations using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) method. Target audience and patient population: The target audience for this guideline includes all clinicians, and the target patient population includes all adults aged 60 years or older with hypertension. Recommendation 1: ACP and AAFP recommend that clinicians initiate treatment in adults aged 60 years or older with systolic blood pressure persistently at or above 150 mm Hg to achieve a target systolic blood pressure of less than 150 mm Hg to reduce the risk for mortality, stroke, and cardiac events. (Grade: strong recommendation, high-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient. Recommendation 2: ACP and AAFP recommend that clinicians consider initiating or intensifying pharmacologic treatment in adults aged 60 years or older with a history of stroke or transient ischemic attack to achieve a target systolic blood pressure of less than 140 mm Hg to reduce the risk for recurrent stroke. (Grade: weak recommendation, moderate-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient. Recommendation 3: ACP and AAFP recommend that clinicians consider initiating or intensifying pharmacologic treatment in some adults aged 60 years or older at high cardiovascular risk, based on individualized assessment, to achieve a target systolic blood pressure of less than 140 mm Hg to reduce the risk for stroke or cardiac events. (Grade: weak recommendation, low-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient.

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians

Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary

Updated National and International Hypertension Guidelines: A Review of Current Recommendations

The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure

Guideline-Driven Management of Hypertension: An Evidence-Based Update

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the …

US hypertension management guidelines: a review of the recent past and recommendations for the future

Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children

Blood Pressure Goals: A Moving Target

The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension

Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents

Interpretation for“2014 evidence-based guideline for the management of high blood pressure in adults”in the United States:discussion of the rational treatment of hypertension

The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association

What is New in the ESC Hypertension Guideline?

What Constitutes Adequate Control of High Blood Pressure? Current Considerations

A comprehensive overview of the diagnosis and treatment of hypertension based on the latest hypertension guidelines

Assessing the Existing Professional Exercise Recommendations for Hypertension: A Review and Recommendations for Future Research Priorities

Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007

Screening for hypertension in adults: protocol for evidence reviews to inform a Canadian Task Force on Preventive Health Care guideline update

Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC/AHA Hypertension Guideline